Hiroji Iwata

1.0k total citations · 1 hit paper
26 papers, 238 citations indexed

About

Hiroji Iwata is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Hiroji Iwata has authored 26 papers receiving a total of 238 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 9 papers in Cancer Research. Recurrent topics in Hiroji Iwata's work include Advanced Breast Cancer Therapies (16 papers), Cancer Treatment and Pharmacology (10 papers) and HER2/EGFR in Cancer Research (7 papers). Hiroji Iwata is often cited by papers focused on Advanced Breast Cancer Therapies (16 papers), Cancer Treatment and Pharmacology (10 papers) and HER2/EGFR in Cancer Research (7 papers). Hiroji Iwata collaborates with scholars based in Japan, United States and South Korea. Hiroji Iwata's co-authors include Giuseppe Curigliano, Erika Hamilton, Seock‐Ah Im, Kan Yonemori, Javier Cortés, Sara A. Hurvitz, Sung‐Bae Kim, Giampaolo Bianchini, Tatsuya Toyama and Yali Liu and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Hiroji Iwata

24 papers receiving 235 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

2024 53 citations Javier Cortés, Sara A. Hurvitz et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hiroji Iwata Japan	8	192	122	63	43	37	26	238
T. Valdez United States	6	274 1.4×	153 1.3×	79 1.3×	66 1.5×	40 1.1×	17	326
Brooke Daniel United States	7	170 0.9×	69 0.6×	33 0.5×	58 1.3×	31 0.8×	17	196
IA Mayer United States	9	236 1.2×	170 1.4×	43 0.7×	66 1.5×	88 2.4×	25	297
Peter Schmid United States	5	227 1.2×	113 0.9×	65 1.0×	48 1.1×	27 0.7×	11	268
Míriam Arumí Spain	5	113 0.6×	80 0.7×	37 0.6×	47 1.1×	33 0.9×	13	172
Rinat Yerushalmi Israel	7	139 0.7×	67 0.5×	31 0.5×	47 1.1×	50 1.4×	11	182
HJ Burstein United States	8	188 1.0×	61 0.5×	50 0.8×	84 2.0×	51 1.4×	25	223
Elisa Genovesi Italy	4	251 1.3×	75 0.6×	123 2.0×	157 3.7×	23 0.6×	6	289
Vicente Carañana Spain	7	227 1.2×	90 0.7×	27 0.4×	127 3.0×	22 0.6×	20	262
Lori Marini United States	4	127 0.7×	95 0.8×	22 0.3×	71 1.7×	58 1.6×	10	193

Countries citing papers authored by Hiroji Iwata

Since Specialization

Citations

This map shows the geographic impact of Hiroji Iwata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroji Iwata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroji Iwata more than expected).

Fields of papers citing papers by Hiroji Iwata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroji Iwata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroji Iwata. The network helps show where Hiroji Iwata may publish in the future.

Co-authorship network of co-authors of Hiroji Iwata

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroji Iwata. A scholar is included among the top collaborators of Hiroji Iwata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroji Iwata. Hiroji Iwata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jacot, William, Seock‐Ah Im, Sherene Loi, et al.. (2025). Abstract PS8-03: Exploratory biomarker analysis of Trastuzumab deruxtecan (T-DXd) vs Trastuzumab emtansine (T-DM1) efficacy in human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC) in DESTINY-Breast03 (DB-03). Clinical Cancer Research. 31(12_Supplement). PS8–3. 2 indexed citations

Hamilton, Erika, Sara A. Hurvitz, Seock‐Ah Im, et al.. (2024). Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03.. Journal of Clinical Oncology. 42(16_suppl). 1025–1025. 5 indexed citations

Mukohara, Toru, David Sommerhalder, Kan Yonemori, et al.. (2024). A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 3006–3006. 2 indexed citations

Cortés, Javier, Sara A. Hurvitz, Seock‐Ah Im, et al.. (2024). Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature Medicine. 30(8). 2208–2215. 53 indexed citations breakdown →

Iwata, Hiroji, Yoichi Naito, Masaya Hattori, et al.. (2024). Safety and pharmacokinetics of vepdegestrant in Japanese patients with ER+ advanced breast cancer: a phase 1 study. International Journal of Clinical Oncology. 30(1). 72–82. 4 indexed citations

Naito, Yoichi, Yukinori Ozaki, Hitoshi Tsuda, et al.. (2024). ctDNA monitoring for breast cancer at high risk of recurrence: Interim analysis of JCOG1204A1.. Journal of Clinical Oncology. 42(16_suppl). 518–518. 1 indexed citations

Endo, Yuka, Haruru Kotani, Chiho Kudo, et al.. (2024). Utility of a breast biopsy clip and a point marker system in tailored axillary surgery for patients with breast cancer after neoadjuvant chemotherapy. Breast Cancer. 31(6). 1130–1136. 1 indexed citations

Tokunaga, Eriko, Hiroji Iwata, Tatsuya Toyama, et al.. (2024). Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial. Breast Cancer. 32(1). 132–143. 2 indexed citations

Sasaki, Keita, Ryunosuke Machida, Tadahiko Shien, et al.. (2024). Status of incremental costs of first-line treatment recommended in Japanese clinical guidelines for metastatic breast cancer patients. Japanese Journal of Clinical Oncology. 54(10). 1093–1099. 1 indexed citations

10.

Rugo, Hope, Giuseppe Curigliano, Carlos H. Barrios, et al.. (2024). Abstract PO1-05-09: ASCENT-07: A phase 3, randomized, open-label study of sacituzumab govitecan versus treatment of physician’s choice in patients with HR+/HER2– inoperable, locally advanced, or metastatic breast cancer post-endocrine therapy. Cancer Research. 84(9_Supplement). PO1–5. 6 indexed citations

11.

Sawaki, Masataka, et al.. (2023). Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan. The Breast. 70. 1–7. 10 indexed citations

12.

Irie, Kei, Naoya Hashimoto, Jun‐ichi Morishige, et al.. (2023). Effects ofABCB1andABCG2Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18). Anticancer Research. 43(3). 1283–1289. 3 indexed citations

13.

Uchida, Megumi, Toshi A. Furukawa, Takuhiro Yamaguchi, et al.. (2023). Optimization of smartphone psychotherapy for depression and anxiety among patients with cancer using the multiphase optimization strategy (MOST) framework and decentralized clinical trial system (SMartphone Intervention to LEssen depression/Anxiety and GAIN resilience: SMILE AGAIN project): a protocol for a randomized controlled trial. Trials. 24(1).

14.

Hurvitz, Sara A., Roberto Hegg, Wei‐Pang Chung, et al.. (2023). Abstract GS2-02: GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03. Cancer Research. 83(5_Supplement). GS2–2. 7 indexed citations

15.

Endo, Yuka, Nanae Horisawa, Yuri Ozaki, et al.. (2022). Impact of Tumor Progression on Survival During Neoadjuvant Chemotherapy in Breast Cancer: A Cohort Study. Anticancer Research. 42(7). 3735–3742. 3 indexed citations

16.

Iwata, Hiroji, Aditya Bardia, Simon Lord, et al.. (2022). Abstract CT517: Amcenestrant, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/HER2- advanced breast cancer (aBC): combined biomarker analyses from a Phase 1/2 study in postmenopausal women and a Phase 1 study in postmenopausal Japanese women. Cancer Research. 82(12_Supplement). CT517–CT517. 1 indexed citations

17.

Hamilton, Erika, Winnie Yeo, Sung‐Bae Kim, et al.. (2022). Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.. Journal of Clinical Oncology. 40(16_suppl). 1000–1000. 11 indexed citations

18.

Hart, Lowell L., José Baselga, Hope S. Rugo, et al.. (2012). Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets).. Journal of Clinical Oncology. 30(27_suppl). 102–102.

19.

Gnant, Michael, José Baselga, Hope S. Rugo, et al.. (2012). Effects of everolimus (EVE) on disease progression in bone and bone markers (BM) in patients (pts) with bone metastases (mets).. Journal of Clinical Oncology. 30(15_suppl). 512–512. 5 indexed citations

20.

Iwase, H., et al.. (1997). The clinical value of microsatellite instability and a loss in heterozygosity in sporadic breast cancers. Breast Cancer. 4(4). 234–238. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact